Navigation Links
Medivation Reports First Quarter 2009 Financial Results and Provides Corporate Update
Date:5/11/2009

nned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the timing of clinical trial initiation and enrollment, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, difficulties or delays in obtaining regulatory approval, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, manufacturing of Medivation's product candidates, competition with Medivation's product candidates should they receive marketing approval, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarter ended March 31, 2009 filed today with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Medivation to Announce Early Positive Data from Phase 1-2 Hormone Refractory Prostate Cancer Trial and Host Conference Call and Webcast on Monday, November 5, 2007
2. Medivation Plans to Initiate Pivotal Confirmatory Phase 3 Trial of Dimebon(TM) for Alzheimers Disease in Second Quarter of 2008
3. Medivation to Present at Cowen and Companys 28th Annual Health Care Conference
4. Medivation Announces Participation in Upcoming Conferences
5. Medivation Announces Participation in 27th Annual J.P. Morgan Healthcare Conference
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation to Host Conference Call and Slide Presentation at 4:30 p.m. EST Wednesday, February 25, to Discuss New MDV3100 Efficacy and Safety Data From Trial in Castration-Resistant Prostate Cancer Patients
8. Medivation Announces Fourth Quarter and Year-End 2008 Teleconference and Webcast on March 16, 2009
9. Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer
10. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... , ... September 03, 2015 , ... ... Scholarship applications are open for spring 2016. Scholarships are awarded two times each ... For The Warriors® is a national nonprofit dedicated to restoring a sense of ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... landscape by connecting accredited and institutional investors to real estate investment opportunities nationwide, ... to meet demand from both investors and sponsoring real estate companies. ...
(Date:9/3/2015)... ... September 03, 2015 , ... The Linda Hall Library 2015 ... a comet, the IceCube observatory at the South Pole, and the interior of life-extending ... Lecture Series for the world's foremost independently funded research library devoted to science, engineering, ...
(Date:9/3/2015)... , ... September 03, 2015 , ... Dr. Robert Winchell ... Trauma, Burns, Critical and Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. ... is a nationally renowned expert in care for the critically injured and the development, ...
(Date:9/3/2015)... ... 2015 , ... Atlantic Information Services, Inc. (AIS) is pleased ... for a Rapidly Changing Marketplace.” In this Sept. 16 program, pharmacy benefit experts ... plan sponsors are adopting bold, innovative strategies to control soaring specialty pharmacy and ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Spouse/Caregiver Scholarships Now Open for Spring 2016 2Health News:RealtyShares Announces Mezzanine Financing Products 2Health News:RealtyShares Announces Mezzanine Financing Products 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 2Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 3Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 4Health News:Facing the Frontiers of Science and Technology The Linda Hall Library Announces 2015 Fall Lecture Series Featuring Experiences from the South Pole to Outer Space 5Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2
... the Calcutta High Court claiming that the failure of West ... directives in keeping the metropolis clean had led to the ... has died and several others are suffering from dengue with ... ,The petitioner's lawyer Idris Ali claimed before a division ...
... Recent research by Canadian scientists has revealed that ... of autism//. ,McGill University Health Center scientists ... in 28,000 children and reported their findings in ... that autism rates were actually higher in children ...
... study has found that fifty percent of adults who ... during their childhood thereby linking childhood //obesity to the ... in adulthood. ,Metabolic syndrome is a cluster of ... pressure, low levels of HDL "good" cholesterol, high fasting ...
... women who are at risk for infertility and needing ... in vitro when immature follicles were removed from their ... at the Northwestern University have created a new technology ... normal follicular maturation in vitro and helped maintain a ...
... to a report by Dr. Jack Tu it was found ... factors, treatments//, and outcomes of heart disease for the more ... Canadian Cardiovascular Outcomes Research Team (CCORT) Atlas Editor and Senior ... there is an East to West gradient in terms of ...
... in the United States to begin studies about a vaccine ... smoking//. ,Nic vax, the name of the vaccine is ... on the shelves in 2 years time. ,The ... and impairs them. This results in obliterating the urge to ...
Cached Medicine News:Health News:A three-dimensional Culture System ensures Female Fertility 2Health News:Location Influences Mortality Rate of Cardiovascular Diseases 2
(Date:9/3/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/4q3mv2/investigation ) has announced ... Olmesartan Market, 2010-2019" report to their offering. ... by Sankyo Pharmaceuticals Co., Ltd and was patented in ... by FDA to enter the American market in May. ... the world after it succeeded in the US market. ...
(Date:9/3/2015)... Pharma major Lupin Limited ... (Lupin) has launched its Duloxetine 40 mg Delayed-Release ... generic Duloxetine formulation to become available in 40 ... this new strength to market, as it adds ... flexibility of treatment.      (Photo: ...
(Date:9/3/2015)... India , September 3, 2015 ... Metallic compounds, Organosulfurs, Organic acids, Phenolics, and Others) and ... & beverage, Paints & coatings, and Others) - Global ... and segments the Biocides Market with an analysis and ... as value. Browse   88 tables ...
Breaking Medicine Technology:China Olmesartan Investigation Market Report 2010-2019 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 2Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 3Lupin Launches First-ever Duloxetine 40mg Delayed-Release Capsules in the US 4Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5
The workhorse electric system....
... BD Xstar Blade includes a specially designed, ... in prodedure and handling. The Xstar ... process for manufacturing surgical blades. This ... The arch style, single-bevel geometry allows ...
... The BD Safety Knife with BD ... retractable shield that protects the blade in ... technology is based on a grind-less process ... process yields outstanding sharpness and consistency. ...
... BD Xstar Blade includes a specially designed, ... in prodedure and handling. The Xstar ... process for manufacturing surgical blades. This ... The arch style, single-bevel geometry allows ...
Medicine Products: